News articles about HTG Molecular Diagnostics (NASDAQ:HTGM) have trended somewhat positive on Sunday, according to Accern Sentiment. The research group rates the sentiment of media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. HTG Molecular Diagnostics earned a coverage optimism score of 0.13 on Accern’s scale. Accern also assigned media coverage about the medical research company an impact score of 45.1344846646349 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
HTG Molecular Diagnostics (HTGM) opened at 1.78 on Friday. The company has a 50 day moving average price of $1.88 and a 200-day moving average price of $2.33. The firm’s market capitalization is $20.38 million. HTG Molecular Diagnostics has a 1-year low of $1.20 and a 1-year high of $4.45.
HTG Molecular Diagnostics (NASDAQ:HTGM) last announced its quarterly earnings results on Tuesday, August 8th. The medical research company reported ($0.60) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.60). The firm had revenue of $1.76 million during the quarter, compared to analyst estimates of $1.80 million. HTG Molecular Diagnostics had a negative return on equity of 1,538.49% and a negative net margin of 432.74%. On average, analysts forecast that HTG Molecular Diagnostics will post ($2.42) EPS for the current fiscal year.
A number of brokerages have recently commented on HTGM. Zacks Investment Research lowered HTG Molecular Diagnostics from a “hold” rating to a “sell” rating in a research note on Tuesday, August 15th. ValuEngine raised HTG Molecular Diagnostics from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 12th. Finally, HC Wainwright set a $6.00 price objective on HTG Molecular Diagnostics and gave the stock a “buy” rating in a research note on Wednesday, August 9th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and two have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $5.75.
COPYRIGHT VIOLATION NOTICE: This piece was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of United States & international copyright law. The legal version of this piece can be accessed at https://ledgergazette.com/2017/09/17/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-htg-molecular-diagnostics-htgm-stock-price.html.
In related news, major shareholder Holdings A/S Novo sold 1,149,813 shares of the business’s stock in a transaction that occurred on Friday, August 25th. The stock was sold at an average price of $1.81, for a total value of $2,081,161.53. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold 1,659,998 shares of company stock valued at $3,073,696 in the last quarter. 7.60% of the stock is owned by company insiders.
About HTG Molecular Diagnostics
HTG Molecular Diagnostics, Inc is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development.
Receive News & Ratings for HTG Molecular Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.